CST3 and chronic kidney disease: Estimated CKD prevalence would be reduced in all age groups except in people over 75, and those still classified as CKD would be at higher risk of adverse consequences, as others have found.[13,20,22,24] This study also adds that targeted use of cystatin C in people with one or two abnormal biomarkers (Scr-based eGFR<60ml/min/1.73m2 and / or uACR≥3mg/mmol, about 12% of the population in this study) would further reduce the estimated prevalence of people labelled as having CKD and likely improve their risk stratification.